Condition Results Operations Financial Review Results Operations Abbott revenues derived primarily sale broad line health care products short-term receivable arrangements Patent protection licenses technological performance features inclusion Abbott products contract impact products sold price controls competition rebates impact net selling prices products foreign currency translation impacts measurement net sales costs Abbott primary products nutritional products branded generic pharmaceuticals diagnostic testing products cardiovascular neuromodulation products The following table details sales reportable segment three months nine months ended September 30 Percent changes versus prior year based unrounded numbers Net Sales External Customers millions Three Months Ended Sept 30 2017 Three Months Ended Sept 30 2016 Total Change Impact Foreign Exchange Total Change Excl Foreign Exchange Established Pharmaceutical Products 1,171 1,012 15.7 1.4 14.3 Nutritional Products 1,768 1,755 0.8 0.8 Diagnostic Products 1,279 1,213 5.4 0.2 5.2 Cardiovascular Neuromodulation Products 2,224 708 214.1 1.0 213.1 Total Reportable Segments 6,442 4,688 37.4 0.5 36.9 Other 387 614 36.9 1.3 38.2 Net Sales 6,829 5,302 28.8 0.6 28.2 Total U.S 2,313 1,645 40.6 40.6 Total International 4,516 3,657 23.5 0.9 22.6 Net Sales External Customers millions Nine Months Ended Sept 30 2017 Nine Months Ended Sept 30 2016 Total Change Impact Foreign Exchange Total Change Excl Foreign Exchange Established Pharmaceutical Products 3,142 2,880 9.1 1.1 8.0 Nutritional Products 5,141 5,166 0.5 0.6 0.1 Diagnostic Products 3,710 3,557 4.3 0.8 5.1 Cardiovascular Neuromodulation Products 6,587 2,175 202.9 0.4 203.3 Total Reportable Segments 18,580 13,778 34.8 0.3 35.1 Other 1,221 1,742 29.9 0.4 29.5 Net Sales 19,801 15,520 27.6 0.3 27.9 Total U.S 6,997 4,831 44.8 44.8 Total International 12,804 10,689 19.8 0.4 20.2 Note In order compute results excluding impact exchange rates current year U.S dollar sales multiplied divided appropriate current year average foreign exchange rates amounts multiplied divided appropriate prior year average foreign exchange rates 21 Table Contents Net sales growth third quarter first nine months 2017 driven acquisition St Jude Medical Inc St Jude Medical completed January 4 2017 well growth Established Pharmaceutical Products Diagnostic Products segments excluding impact foreign exchange Beginning first quarter 2017 Abbott cardiovascular neuromodulation business included results historical Vascular Products segment results businesses acquired St Jude Medical date acquisition The decrease Other category third quarter first nine months 2017 reflects sale Abbott Medical Optics AMO segment Johnson Johnson partially offset double-digit growth Abbott Diabetes Care business The AMO segment included Abbott results non-reportable segment February 27 2017 Excluding St Jude Medical acquisition AMO results impact foreign exchange total net sales increased 6.0 percent U.S sales increased 0.1 percent international sales increased 8.7 percent third quarter 2017 Excluding St Jude Medical acquisition AMO results impact foreign exchange total net sales increased 4.1 percent U.S sales increased 2.0 percent international sales increased 5.0 percent first nine months 2017 The table provides detail sales category nine months ended September 30 Percent changes versus prior year based unrounded numbers millions Sept 30 2017 Sept 30 2016 Total Change Impact Foreign Exchange Total Change Excl Foreign Exchange Established Pharmaceutical Products Key Emerging Markets 2,413 2,135 13.0 1.4 11.6 Other Emerging Markets 729 745 2.3 0.2 2.5 Nutritionals International Pediatric Nutritionals 1,562 1,664 6.1 1.0 5.1 U.S Pediatric Nutritionals 1,327 1,242 6.8 6.8 International Adult Nutritionals 1,317 1,278 3.0 1.1 4.1 U.S Adult Nutritionals 935 982 4.8 4.8 Diagnostics Core Laboratory 2,964 2,840 4.3 1.1 5.4 Molecular 341 339 0.6 0.5 0.1 Point Care 405 378 7.3 0.1 7.4 Cardiovascular Neuromodulation Rhythm Management 1,574 n/m n/m n/m Electrophysiology 1,001 10 n/m n/m n/m Heart Failure 471 n/m n/m n/m Vascular 2,158 1,905 13.3 0.4 13.7 Structural Heart 793 260 205.5 0.3 205.8 Neuromodulation 590 n/m n/m n/m Key Emerging Markets Established Pharmaceutical Products business include India Russia Brazil China along several markets represent attractive long-term growth opportunities Abbott branded generics product portfolio Excluding effect foreign exchange sales Key Emerging Markets increased 11.6 percent compared first nine months 2016 Strong growth Russia China several countries across Latin America partially offset impact associated implementation new Goods Services Tax GST system India second quarter 2017 Excluding impact GST sales Key Emerging Markets would grown 13.2 percent first nine months 2017 The 2.3 percent decrease Other Emerging Markets first nine months 2017 primarily reflects unfavorable impact Venezuelan operations Excluding Venezuela effect foreign exchange sales Other Emerging Markets increased 4.1 percent versus first nine months 2016 Excluding effect foreign exchange International Pediatric Nutritional sales decreased 5.1 percent first nine months 2017 Challenging conditions infant formula market various emerging markets negatively impacted international performance In U.S above-market Pediatric sales growth 6.8 percent led continued momentum several recently launched infant formula products well growth PediaSure toddler brand Excluding effect foreign exchange International Adult Nutritional sales increased 4.1 percent compared first nine months 2016 led continued market growth across priority geographies U.S Adult Nutritional sales decreased 4.8 percent due competitive market dynamics Excluding effect foreign exchange 5.1 percent increase Diagnostics sales primarily driven share gains Core Laboratory Point Care markets U.S higher sales various international markets During quarter Abbott continued international roll-out recently launched Alinity systems core laboratory including Alinity c clinical chemistry Alinity immunoassay diagnostics Alinity blood plasma screening 22 Table Contents Excluding effect foreign exchange 203.3 percent increase Cardiovascular Neuromodulation Products segment driven acquisition St Jude Medical completed January 4 2017 Excluding impact acquisition well impact foreign exchange sales Cardiovascular Neuromodulation Products segment essentially flat first nine months 2017 versus prior year lower coronary stent sales comparison impact favorable 2016 resolution third-party royalty agreement offset higher Structural Heart endovascular sales The gross profit margin percentage Abbott 50.8 percent third quarter 2017 compared 54.3 percent third quarter 2016 The gross profit margin percentage 47.0 percent first nine months 2017 compared 54.0 percent first nine months 2016 The decrease primarily reflects higher intangible amortization expense inventory step-up amortization related St Jude Medical acquisition Research development expenses increased 210 million 59.3 percent third quarter 2017 increased 543 million 50.3 percent first nine months 2017 due primarily addition acquired St Jude Medical business For nine months ended September 30 2017 research development expenditures totaled 718 million Cardiovascular Neuromodulation Products segment 382 million Diagnostic Products segment 119 million Established Pharmaceutical Products segment 142 million Nutritional Products segment Selling general administrative expenses third quarter first nine months 2017 increased 28.9 percent 31.5 percent respectively due primarily addition acquired St Jude Medical business well incremental expenses integrate St Jude Medical Abbott existing vascular business partially offset impact cost improvement initiatives across various functions businesses On September 30 2016 Abbott recorded expense 947 million adjust holding Mylan N.V ordinary shares due decline fair value securities considered Abbott temporary The adjustment reflected Mylan N.V share price September 30 2016 included Other expense income net line Condensed Consolidated Statement Earnings 2016 In April 2017 Abbott received warning letter U.S Food Drug Administration FDA related manufacturing facility Sylmar CA acquired Abbott January 4 2017 part acquisition St Jude Medical This facility manufactures implantable cardioverter defibrillators cardiac resynchronization therapy defibrillators monitors The warning letter relates FDA observations inspection facility Abbott prepared comprehensive plan corrective actions provided FDA Execution plan progressing 23 Table Contents Business Acquisitions On January 4 2017 Abbott completed acquisition St Jude Medical global medical device manufacturer approximately 23.6 billion including approximately 13.6 billion cash approximately 10 billion Abbott common shares represented approximately 254 million shares Abbott common stock based Abbott closing stock price acquisition date As part acquisition approximately 5.9 billion St Jude Medical debt assumed repaid refinanced Abbott The transaction provides expanded opportunities future growth important part company ongoing effort develop strong diverse portfolio devices diagnostics nutritionals branded generic pharmaceuticals The combined company compete nearly every area cardiovascular market well neuromodulation market Under terms agreement St Jude Medical common share St Jude Medical shareholders received 46.75 cash 0.8708 Abbott common share At Abbott stock price 39.36 reflects closing price January 4 2017 represented value approximately 81 per St Jude Medical common share total purchase consideration 23.6 billion The cash portion acquisition funded combination medium long-term debt issued November 2016 2.0 billion 120-day senior unsecured bridge term loan facility subsequently repaid The preliminary allocation fair value St Jude Medical acquisition shown table The allocation fair value acquisition finalized valuation completed differences preliminary final allocation could material billions Acquired intangible assets non-deductible 15.4 Goodwill non-deductible 14.9 Acquired net tangible assets 3.1 Deferred income taxes recorded acquisition 4.5 Net debt 5.3 Total preliminary allocation fair value 23.6 The goodwill primarily attributable expected synergies combining operations well intangible assets qualify separate recognition The acquired tangible assets consist primarily trade accounts receivable approximately 1.2 billion inventory approximately 1.7 billion current assets 207 million property equipment approximately 1.5 billion long-term assets 471 million The acquired tangible liabilities consist trade accounts payable current liabilities approximately 1.1 billion non-current liabilities approximately 850 million In first nine months 2017 consolidated Abbott results include 4.4 billion sales pre-tax loss approximately 1.2 billion related St Jude Medical acquisition including approximately 1.0 billion intangible amortization 840 million inventory step-up amortization The pre-tax loss excludes acquisition integration restructuring-related costs In 2016 Abbott St Jude Medical agreed sell certain businesses Terumo Corporation approximately 1.12 billion The sale included St Jude Medical Angio-Seal Femoseal vascular closure Abbott Vado Steerable Sheath businesses The sale closed January 20 2017 gain loss recorded Condensed Consolidated Statement Earnings On October 3 2017 Abbott acquired Alere Inc Alere diagnostic device service provider 51.00 per common share cash equated purchase price approximately 4.6 billion As part acquisition Abbott tendered Alere preferred shares total value approximately 0.7 billion In addition approximately 2.96 billion Alere debt assumed subsequently repaid The transaction establishes Abbott leader point care testing expands Abbott global diagnostics presence provides access new products channels geographies Abbott utilized combination cash hand debt fund acquisition See Note 10 Debt Lines Credit details regarding debt utilized acquisition As acquisition Alere completed September 30 2017 Abbott consolidated financial statements include financial condition operating results Alere periods presented herein 24 Table Contents The preliminary allocation fair value Alere acquisition shown table The allocation fair value acquisition finalized valuation completed differences preliminary final allocation could material billions Acquired intangible assets non-deductible 3.3 Goodwill non-deductible 4.1 Acquired net tangible assets 1.0 Deferred income taxes recorded acquisition 0.5 Net debt 2.6 Preferred stock 0.7 Total preliminary allocation fair value 4.6 The goodwill primarily attributable expected synergies combining operations well intangible assets qualify separate recognition The acquired tangible assets consist primarily trade accounts receivable approximately 425 million inventory approximately 440 million current assets 213 million property equipment approximately 480 million long-term assets 147 million The acquired tangible liabilities consist trade accounts payable current liabilities approximately 570 million non-current liabilities approximately 160 million In third quarter 2017 Alere entered agreements sell Triage MeterPro cardiovascular toxicology business assets liabilities related B-type Natriuretic Peptide assay business run Beckman Coulter analyzers Quidel Corporation Quidel The transactions Quidel reflect total purchase price 400 million payable close transaction 240 million payable six annual installments beginning approximately six months close transaction contingent consideration maximum value 40 million In third quarter 2017 Alere entered agreement Siemens Diagnostics Holding II B.V Siemens sell subsidiary Epocal Inc approximately 200 million Alere agreed divest businesses connection review Federal Trade Commission European Commission Abbott agreement acquire Alere The sale Quidel closed October 6 2017 sale Siemens closed October 31 2017 If acquisitions St Jude Medical Alere occurred beginning 2016 unaudited pro forma consolidated net sales would approximately 21.6 billion unaudited pro forma consolidated net loss continuing operations would approximately 875 million first nine months 2016 This includes amortization approximately 955 million inventory step-up 1.3 billion intangibles related St Jude Medical Alere For third quarter 2016 unaudited pro forma consolidated net sales would approximately 7.3 billion unaudited pro forma consolidated net loss continuing operations would approximately 490 million This includes amortization approximately 20 million inventory step-up 425 million intangibles related St Jude Medical Alere For first nine months 2017 unaudited pro forma consolidated net sales would approximately 21.3 billion unaudited pro forma consolidated net earnings continuing operations would approximately 1.6 billion includes 225 million amortization related Alere For third quarter 2017 unaudited pro forma consolidated net sales would approximately 7.3 billion unaudited pro forma consolidated net earnings continuing operations would approximately 515 million includes 75 million amortization related Alere The unaudited pro forma consolidated net earnings continuing operations third quarter first nine months 2017 exclude inventory step-up amortization related St Jude Medical approximately 20 million 840 million respectively recorded 2017 included 2016 unaudited pro forma results noted paragraph The unaudited pro forma information necessarily indicative consolidated results operations would realized St Jude Medical Alere acquisitions completed beginning 2016 meant indicative future results operations combined entity experience On July 17 2017 Abbott commenced tender offer purchase cash 1.77 million outstanding shares Alere Series B Convertible Perpetual Preferred Stock price 402 per share plus accrued unpaid dividends including settlement date tender offer This tender offer subject satisfaction certain conditions including Abbott acquisition Alere upon validly tendered properly withdrawn expiration date tender offer number shares Preferred Stock equaled least majority Preferred Stock issued outstanding expiration tender offer The tender offer expired October 3 2017 All conditions offer satisfied Abbott accepted payment 1.748 million shares Preferred Stock validly tendered properly withdrawn Payment offer price shares made fourth quarter 2017 25 Table Contents Restructuring Plans The results first nine months 2017 reflect charges approved restructuring plans part integration acquisition St Jude Medical well costs related actions associated company plans streamline various operations Abbott recorded employee related severance charges approximately 249 million first nine months 2017 related initiatives Approximately 4 million recognized Cost products sold 76 million recognized Research development approximately 169 million recognized Selling general administrative expense See Note 8 financial statements Restructuring Plans additional information regarding charges Interest Expense Income net Interest expense income net increased 87 million third quarter 2017 366 million first nine months 2017 compared 2016 due primarily 15.1 billion debt issued November 2016 related financing St Jude Medical acquisition closed January 4 2017 Taxes Earnings Continuing Operations Taxes earnings continuing operations reflect estimated annual effective rates include charges interest penalties In first nine months 2017 taxes earnings continuing operations include 435 million tax expense related gain sale AMO business taxed discrete tax rate Earnings discontinued operations net tax 88 million first nine months 2017 primarily reflects recognition net tax benefits result resolution various tax positions related prior years decreases gross amount unrecognized tax benefits approximately 80 million In first nine months 2016 taxes earnings continuing operations includes impact net tax benefit approximately 250 million result resolution various tax positions prior years partially offset unfavorable impact non-deductible foreign exchange losses related Venezuela adjustment Mylan N.V equity investment well recognition deferred taxes associated sale AMO Earnings discontinued operations net tax first nine months 2016 reflects recognition 289 million net tax benefits primarily result resolution various tax positions related prior years The conclusion tax matters decreased gross amount unrecognized tax benefits approximately 546 million 2016 Tax authorities various jurisdictions regularly review Abbott income tax filings Abbott believes reasonably possible recorded amount gross unrecognized tax benefits may decrease 200 million 350 million including cash adjustments within next twelve months result concluding various domestic international tax matters In U.S Abbott federal income tax returns settled 2013 St Jude Medical federal income tax returns settled 2013 except one item Discontinued Operations On February 27 2015 Abbott completed sale developed markets branded generics pharmaceuticals business Mylan Inc Mylan 110 million shares approximately 22 newly formed entity Mylan N.V combined Mylan existing business Abbott developed markets branded generics pharmaceuticals business Mylan N.V publicly traded The shareholder agreement Mylan N.V included voting restrictions prevented Abbott exercising significant influence operating financial policies Mylan N.V In April 2015 Abbott sold 40.25 million 110 million ordinary shares Mylan N.V As result sale Abbott ownership interest Mylan N.V decreased approximately 14 In first nine months 2017 Abbott sold 51 million ordinary shares Mylan N.V received 1.977 billion proceeds Abbott recorded immaterial pre-tax gain first nine months 2017 recognized Other expense income net line Condensed Consolidated Statement Earnings As result share sales Abbott ownership interest Mylan N.V decreased approximately 14 3.4 On January 1 2013 Abbott completed separation AbbVie Inc AbbVie formed hold Abbott research-based proprietary pharmaceuticals business Abbott retained liabilities U.S federal foreign income taxes income prior separation well certain non-income related taxes attributable AbbVie business prior separation AbbVie generally liable taxes attributable business 26 Table Contents Earnings discontinued operations net tax 88 million 288 million first nine months 2017 2016 respectively driven primarily recognition net tax benefits result resolution various tax positions related AbbVie operations years prior separation In first quarter 2016 Abbott received additional 25 million proceeds related expiration holdback agreement associated sale animal health business reported after-tax gain sale discontinued operations 16 million Assets Liabilities Held Disposition In September 2016 Abbott announced entered definitive agreement sell AMO vision care business Johnson Johnson 4.325 billion cash subject customary purchase price adjustments cash debt working capital The decision sell AMO reflects Abbott proactive shaping portfolio line strategic priorities In February 2017 Abbott completed sale AMO Johnson Johnson recognized pre-tax gain 1.163 billion including working capital adjustments reported Other expense income net line Condensed Consolidated Statement Earnings first nine months 2017 Abbott recorded after-tax gain 728 million first nine months 2017 related sale AMO The operating results AMO date sale continued included Earnings loss continuing operations qualify reporting discontinued operations For three months ended September 30 2017 2016 AMO earnings taxes included Abbott consolidated earnings nil 2 million respectively For first nine months ended September 30 2017 2016 AMO losses taxes included Abbott consolidated earnings 18 million 42 million respectively The following assets liabilities business reported held disposition Abbott Condensed Consolidated Balance Sheet December 31 2016 millions December 31 2016 Trade receivables net 222 Total inventories 240 Prepaid expenses current assets 51 Current assets held disposition 513 Net property equipment 247 Intangible assets net amortization 529 Goodwill 1,966 Deferred income taxes assets 11 Non-current assets held disposition 2,753 Total assets held disposition 3,266 Trade accounts payable 71 Salaries wages commissions accrued liabilities 174 Current liabilities held disposition 245 Post-employment obligations deferred income taxes long-term liabilities 59 Total liabilities held disposition 304 27 Table Contents Liquidity Capital Resources September 30 2017 Compared December 31 2016 The reduction cash cash equivalents 18.6 billion December 31 2016 11.0 billion September 30 2017 reflects use cash fund cash portion St Jude Medical acquisition repayments debt pension contributions dividends paid first nine months 2017 partially offset cash generated operations proceeds disposition businesses sale portion Abbott investment Mylan ordinary shares Net cash operating activities first nine months 2017 totaled 3.9 billion increase 1.9 billion prior year due primarily favorable impact improved working capital management well acquisition St Jude Medical businesses lower pension contributions The Other net line Net cash operating activities first nine months 2017 562 million includes impact improved working capital management approximately 435 million tax expense associated disposition businesses yet paid Other net also includes contributions defined benefit pension plans 335 million Other net Net cash operating activities first nine months 2016 includes contributions defined benefit pension plans 540 million well approximately 140 million cash taxes paid related disposition businesses Other net 2016 also includes non-cash impact approximately 539 million net tax benefits primarily associated resolution various tax positions prior years The foreign currency loss related Venezuela first nine months 2016 reduced Abbott cash approximately 410 million shown Effect exchange rate changes cash cash equivalents line within Condensed Consolidated Statement Cash Flows Abbott expects fund cash dividends capital expenditures investments businesses cash flow operating activities cash hand short-term investments borrowings Working capital 13.4 billion September 30 2017 20.1 billion December 31 2016 The 6.7 billion decrease working capital 2017 primarily due reduction Cash cash equivalents discussed improved working capital management Since January 2010 Venezuela designated highly inflationary economy U.S GAAP In 2014 2015 government Venezuela operated multiple mechanisms exchange bolivars U.S dollars These mechanisms included CENCOEX SICAD SIMADI rates stood 6.3 13.5 approximately 200 respectively December 31 2015 In 2015 Abbott continued use CENCOEX rate 6.3 Venezuelan bolivars U.S dollar report results financial position cash flows related operations Venezuela since Abbott continued qualify exchange rate pay import various products Venezuela On February 17 2016 Venezuelan government announced three-tier exchange rate system would reduced two rates renamed DIPRO DICOM rates The DIPRO rate official rate food medicine imports adjusted 6.3 10 bolivars per U.S dollar The DICOM rate floating market rate published daily Venezuelan central bank end first quarter 2016 approximately 263 bolivars per U.S dollar As result decreasing government approvals convert bolivars U.S dollars pay intercompany accounts well accelerating deterioration economic conditions country Abbott concluded appropriate move DICOM rate end first quarter 2016 As result Abbott recorded foreign currency exchange loss 481 million first nine months 2016 revalue net monetary assets Venezuela Abbott continuing use DICOM rate report results operations remeasure net monetary assets Venezuela end quarter As September 30 2017 Abbott Venezuelan operations represented less 0.01 Abbott consolidated assets additional foreign currency losses related Venezuela expected material At September 30 2017 Abbott long-term debt rating BBB Standard Poor Corporation Baa3 Moody Investors Service Abbott expects maintain investment grade rating Abbott readily available financial resources including lines credit 5.0 billion September 30 2017 expire 2019 On October 3 2017 connection Alere acquisition Abbott borrowed 1.7 billion lines credit Abbott borrowings bear interest based Eurodollar rate plus applicable margin based Abbott credit ratings In September 2014 board directors authorized repurchase 3.0 billion Abbott common shares time time The 2014 authorization addition 512 million unused portion previous program announced June 2013 In first nine months 2016 Abbott repurchased 10.4 million shares cost 408 million program authorized 2014 On April 27 2016 board directors authorized issuance sale general corporate purposes 75 million common shares would result proceeds 3 billion No shares issued authorization In first three quarters 2017 Abbott declared quarterly dividend 0.265 per share common shares represents increase approximately 2 0.26 per share quarterly dividend declared first three quarters 2016 28 Table Contents Recently Issued Accounting Standards In August 2017 Financial Accounting Standards Board FASB issued Accounting Standards Update ASU 2017-12 Targeted Improvements Accounting Hedging Activities makes changes designation measurement guidance qualifying hedging relationships presentation hedge results The standard becomes effective Abbott beginning first quarter 2019 early adoption permitted Abbott currently evaluating effect ASU 2017-12 consolidated financial statements In March 2017 FASB issued ASU 2017-07 Compensation Retirement Benefits Topic 715 Improving Presentation Net Periodic Pension Cost Net Periodic Postretirement Benefit Cost changes financial statement presentation requirements pension postretirement benefit expense While service cost continue reported financial statement line items current employee compensation costs ASU requires components pension postretirement benefit expense presented separately service cost outside subtotal income operations The standard becomes effective Abbott beginning first quarter 2018 early adoption permitted Abbott currently evaluating impact ASU 2017-07 consolidated financial statements In October 2016 FASB issued ASU 2016-16 Income Taxes Topic 740 Intra-Entity Transfers Assets Other Than Inventory requires recognition income tax effects intercompany sales transfers assets inventory period transfer occurs The standard becomes effective Abbott beginning first quarter 2018 early adoption permitted Abbott currently evaluating impact ASU 2016-16 consolidated financial statements In February 2016 FASB issued ASU 2016-02 Leases requires lessees recognize assets liabilities leases balance sheet The standard becomes effective Abbott beginning first quarter 2019 early adoption permitted Adoption requires application new guidance periods presented Abbott currently evaluating impact new guidance consolidated financial statements In January 2016 FASB issued ASU 2016-01 Financial Instruments Recognition Measurement Financial Assets Financial Liabilities provides new guidance recognition measurement presentation disclosure financial assets liabilities The standard becomes effective Abbott beginning first quarter 2018 early adoption permitted Abbott currently evaluating effect standard consolidated financial statements related disclosures In May 2014 FASB issued ASU 2014-09 Revenue Contracts Customers provides single comprehensive model accounting revenue contracts customers supersede existing revenue recognition guidance The standard becomes effective Abbott first quarter 2018 Abbott revenues primarily comprised product sales Abbott made substantial progress evaluation new standard including detailed review Abbott revenue streams contracts Based work performed date Abbott currently expect adoption new standard material impact consolidated financial statements Abbott continuing evaluate effect standard consolidated financial statements including new disclosure requirements Abbott continue monitor additional modifications clarifications interpretations undertaken FASB may impact Abbott current conclusions Abbott currently expecting use modified retrospective method adopt standard Legislative Issues Abbott primary markets highly competitive subject substantial government regulations throughout world Abbott expects debate continue availability method delivery payment health care products services It possible predict extent Abbott health care industry general might adversely affected factors future A complete discussion factors contained Item 1 Business Item 1A Risk Factors 2016 Annual Report Form 10-K Private Securities Litigation Reform Act 1995 A Caution Concerning Forward-Looking Statements Under safe harbor provisions Private Securities Litigation Reform Act 1995 Abbott cautions investors forward-looking statements projections made Abbott including made document subject risks uncertainties may cause actual results differ materially projected Economic competitive governmental technological factors may affect Abbott operations discussed Item 1A Risk Factors 2016 Annual Report Form 10-K 29 Table Contents PART I FINANCIAL INFORMATION Item 3 Quantitative Qualitative